William Renwick

1.4k total citations
14 papers, 278 citations indexed

About

William Renwick is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, William Renwick has authored 14 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in William Renwick's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). William Renwick is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Acute Lymphoblastic Leukemia research (5 papers). William Renwick collaborates with scholars based in Australia, New Zealand and United States. William Renwick's co-authors include Alpha Tsui, Daniel Steinfort, Louis Irving, Sant‐Rayn Pasricha, Phillip Antippa, Matthew Conron, Ruth Pettengell, Michael Green, Michael Haeusler and Annabel Tuckfield and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Annals of Thoracic Surgery.

In The Last Decade

William Renwick

14 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
William Renwick Australia	8	118	69	68	60	45	14	278
A Van Hoof Belgium	8	86 0.7×	29 0.4×	15 0.2×	63 1.1×	49 1.1×	9	221
John P. Farnen United States	9	32 0.3×	63 0.9×	49 0.7×	51 0.8×	53 1.2×	16	265
Shir‐Jing Ho Australia	9	26 0.2×	75 1.1×	36 0.5×	162 2.7×	67 1.5×	22	273
Arif Alam United Arab Emirates	9	19 0.2×	162 2.3×	133 2.0×	126 2.1×	114 2.5×	26	333
H. Dieterich Germany	5	47 0.4×	17 0.2×	105 1.5×	88 1.5×	17 0.4×	18	349
Philip L. Cimo United States	8	61 0.5×	16 0.2×	17 0.3×	223 3.7×	42 0.9×	11	345
G. Armengol France	8	32 0.3×	30 0.4×	10 0.1×	30 0.5×	33 0.7×	21	187
Francesca Palombi Italy	9	32 0.3×	181 2.6×	125 1.8×	57 0.9×	55 1.2×	18	321
Paweł Kurzawa Poland	12	145 1.2×	62 0.9×	72 1.1×	26 0.4×	6 0.1×	32	343
M. Carmen Gonzalez-Vela Spain	11	92 0.8×	53 0.8×	22 0.3×	23 0.4×	12 0.3×	16	292

Countries citing papers authored by William Renwick

Since Specialization

Citations

This map shows the geographic impact of William Renwick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Renwick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Renwick more than expected).

Fields of papers citing papers by William Renwick

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Renwick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Renwick. The network helps show where William Renwick may publish in the future.

Co-authorship network of co-authors of William Renwick

This figure shows the co-authorship network connecting the top 25 collaborators of William Renwick. A scholar is included among the top collaborators of William Renwick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Renwick. William Renwick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Chong, Geoffrey, Colm Keane, Sze-Ting Lee, et al.. (2023). Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study. Leukemia. 37(5). 1092–1102. 11 indexed citations

Quach, Hang, Masa Lasica, Anna Kalff, et al.. (2021). A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.. Journal of Clinical Oncology. 39(15_suppl). TPS8055–TPS8055. 4 indexed citations

Hawkes, Eliza A., Geoffrey Chong, Charmaine Smith, et al.. (2020). Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study. Blood. 136(Supplement 1). 43–44. 10 indexed citations

Hawkes, Eliza A., Charmaine Smith, Leonid Churilov, et al.. (2019). AvR-CHOP: Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 134(Supplement_1). 5332–5332. 2 indexed citations

Façon, Thierry, Cyrille Hulin, Meletios Α. Dimopoulos, et al.. (2015). A Frailty Scale Predicts Outcomes of Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant Treated with Continuous Lenalidomide Plus Low-Dose Dexamethasone on the First Trial. Blood. 126(23). 4239–4239. 11 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2014). Toxicity Is Not Associated with Age or Comorbidity Score in a Randomised Study of Oral Fludarabine and Cyclophosphamide and IV Rituximab (FCR) As First-Line Therapy of Fit, Elderly Patients with Chronic Lymphocytic Leukemia (CLL). Blood. 124(21). 4695–4695. 4 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2014). A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity. Blood. 124(21). 3325–3325. 11 indexed citations

Lingaratnam, Senthil, Leon J. Worth, Stephen Guy, et al.. (2013). Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot. Internal Medicine Journal. 43(9). 979–986. 7 indexed citations

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2012). A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. Blood. 120(21). 436–436. 11 indexed citations

10.

Mulligan, Stephen P., Devinder Gill, Paul Turner, et al.. (2011). 5.25 Safety and Tolerability of Oral Fludarabine, with or without Oral Cyclophosphamide and Intravenous Rituximab Therapy, in Previously Untreated Patients with Chronic Lymphocytic Leukaemia Aged 65 Years or Older: Second Interim Analysis from the Australasian Leukaemia and Lymphoma Group and CLL Australian Research Consortium CLL5 Study. Clinical Lymphoma Myeloma & Leukemia. 11. S259–S260. 1 indexed citations

11.

Steinfort, Daniel, Matthew Conron, Alpha Tsui, et al.. (2010). Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for the Evaluation of Suspected Lymphoma. Journal of Thoracic Oncology. 5(6). 804–809. 111 indexed citations

12.

Mulligan, Stephen P., Devinder Gill, William Renwick, et al.. (2010). The Safety and Tolerability of Oral Fludarabine, ±oral Cyclophosphamide and Iv Rituximab Therapy In Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years – Interim Analysis From the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study.. Blood. 116(21). 699–699. 5 indexed citations

13.

Renwick, William, Ruth Pettengell, & Michael Green. (2009). Use of Filgrastim and Pegfilgrastim to Support Delivery of Chemotherapy. BioDrugs. 23(3). 175–186. 42 indexed citations

14.

Renwick, William, et al.. (2006). Recombinant Activated Factor VII: Treating Postoperative Hemorrhage in Cardiac Surgery. The Annals of Thoracic Surgery. 81(3). 875–879. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact